Dr. Christopher A. Smith, M.D.

Medicare patients and services

Medicare patients, 2024

658

Services billed

32,459

Patients’ average age

71

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 23 companies reported 265 payments worth $112,211 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $2,650,793 in research payments for these studies, mostly to the institutions running them.

• A phase 3 multicenter placebocontrolled randomized observerblinded trial to evaluate the efficacy safety tolerability immunogenicity and lot consistency of a 6VALENT ospabased lyme disease vaccine in healthy participa…
  Pfizer Inc.
• A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
  Pfizer Inc.
• Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary D…
  AstraZeneca Pharmaceuticals LP
• A phase 3 placebocontrolled doubleblinded randomized study to evaluate the safety tolerability and immunogenicity of different vaccination schedules of 6VALENT ospabased lyme disease vaccine VLA15 in healthy adult par…
  Pfizer Inc.
• A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine,…
  Merck Sharp & Dohme LLC
• A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
  AstraZeneca UK Limited
• A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
  Pfizer Inc.
• A prospective cohort study of patients with refractory or unexplained
  GlaxoSmithKline, LLC.
• Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
  Sanofi Pasteur Inc. · Active, not recruiting · NCT06824181
• A 52-week, randomised, double-blind, double-dummy, parallel group, mul
  GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.